Neurogene (NGNE) Amortization of Deferred Charges (2014 - 2020)
Neurogene (NGNE) reported Amortization of Deferred Charges of $253000.0 for Q3 2020, up 954.17% on a YoY basis from $24000.0 in Q4 2019, and up 8333.33% quarter-over-quarter from $3000.0 in Q2 2020.
Neurogene (NGNE) Amortization of Deferred Charges (2014 - 2020) Analysis & Trends
Neurogene has reported Amortization of Deferred Charges for 3 years, with the latest figure at $253000.0 in Q3 2020.
- For the quarter ending Q3 2020, Amortization of Deferred Charges rose 954.17% year-over-year to $253000.0; the trailing twelve-month figure through Sep 2020 stood at $808000.0 (up 963.16% YoY), and the FY2014 full-year result was $320000.0, up 2185.71% from the prior year.
- Amortization of Deferred Charges for Q3 2020 stood at $253000.0, up from $3000.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $528000.0 in Q1 2020, with the low at $3000.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Neurogene | 216.17 Mn | 216.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 253,000.00 |
| Sep 30, 2020 | 253,000.00 |
| Jun 30, 2020 | 3,000.00 |
| Jun 30, 2020 | 3,000.00 |
| Mar 31, 2020 | 528,000.00 |
| Mar 31, 2020 | 528,000.00 |
| Sep 30, 2019 | 24,000.00 |
| Sep 30, 2019 | 24,000.00 |
| Jun 30, 2019 | 31,000.00 |
| Jun 30, 2019 | 31,000.00 |
| Mar 31, 2019 | 21,000.00 |
| Mar 31, 2019 | 21,000.00 |
| Mar 31, 2014 | 320,000.00 |
| Mar 31, 2014 | 320,000.00 |